• Jillian L Perry, Marc P Kai, Kevin G Reuter, Charles Bowerman, J Christopher Luft, and Joseph M DeSimone.
• Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, North Carolina, USA, perryjl@email.unc.edu.
• Cancer Treat. Res. 2015 Jan 1; 166: 275-91.

AbstractNanoparticle properties such as size, shape, deformability, and surface chemistry all play a role in nanomedicine drug delivery in cancer. While many studies address the behavior of particle systems in a biological setting, revealing how these properties work together presents unique challenges on the nanoscale. "Calibration-quality" control over such properties is needed to draw adequate conclusions that are independent of parameter variability. Furthermore, active targeting and drug loading strategies introduce even greater complexities via their potential to alter particle pharmacokinetics. Ultimately, the investigation and optimization of particle properties should be carried out in the appropriate preclinical tumor model. In doing so, translational efficacy improves as clinical tumor properties increase. Looking forward, the field of nanomedicine will continue to have significant clinical impacts as the capabilities of nanoparticulate drug delivery are further enhanced.

13 keywords...

hide…